NCT03304678View on ClinicalTrials.gov

Discovery of Sirolimus Sensitive Biomarkers in Blood

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 4, 2017

Primary Completion Date

March 9, 2025

Study Completion Date

March 14, 2025

Conditions
Lymphangioleiomyomatosis
Interventions
DRUG

Sirolimus 2mg

Patients with LAM, whose treating physicians have decided that they need to start treatment with sirolimus will be referred to the NIH Clinical Center for these studies.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT03304678 - Discovery of Sirolimus Sensitive Biomarkers in Blood | Biotech Hunter | Biotech Hunter